Cerecor blasted as its second clinical roll of the dice in days comes up snake eyes
Just a few days after Cerecor was pummeled $CERC by the news that its lead depression drug, CERC-301, failed a mid-stage study, the microcap company has been forced to admit that its top drug overall flopped in a Phase II for nicotine withdrawal.
CERC-501, recently the subject of some considerable market buzz after a similar treatment from Alkermes scored positive data in two late-stage trials, failed the trial of 71 heavy smokers. But the biotech now plans to soldier on in major depression, looking to see if it can make progress in a field littered with the corpses of dead drug programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.